The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in vitro fertilization

This publication has 27 references indexed in Scilit:

• Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
  Fertility and Sterility, 2004
• Diminished ovarian reserve and access to care
  Fertility and Sterility, 2004
• High follicle-stimulating hormone levels should not necessarily lead to the exclusion of subfertile patients from treatment
  Fertility and Sterility, 2004
• Use of Stimulated Serum Estradiol Measurements for the Prediction of Hyperresponse to Ovarian Stimulation in in Vitro Fertilization (IVF)
  Journal of Assisted Reproduction and Genetics, 2004
• A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment
  Human Reproduction, 2003
• Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study
  Human Reproduction, 2003
• Antimüllerian hormone serum levels: a putative marker for ovarian aging
  Fertility and Sterility, 2002
• A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization
  Fertility and Sterility, 2001
• Relative influence of serum follicle stimulating hormone, age and other factors on ovarian response to gonadotrophin stimulation
  BJOG: An International Journal of Obstetrics and Gynaecology, 1994
• PROGNOSTIC ASSESSMENT OF FEMALE FECUNDITY
  The Lancet, 1987